Humboldt Fund

Humboldt Fund, founded in 2020 and based in New York, is a venture capital firm focused on investing in the biotech revolution. The fund specializes in early-stage investments in synthetic biology, targeting industries that are transforming the way chemicals, materials, foods, and medicines are made. Humboldt’s mission is to back pioneers in engineering, physical sciences, and life sciences, supporting groundbreaking technologies with the potential to disrupt global markets and solve critical challenges. Key areas of investment include foodtech, healthcare, energy, and advanced materials, with a strong emphasis on synthetic biology and bio-manufacturing. Notable portfolio companies include Metagenomi, Debut Biotech, and Finless Foods, all of which are at the forefront of biotechnological innovation. Humboldt aims to create both economic value and global impact by fostering these revolutionary technologies. Humboldt primarily invests in pre-seed, seed, and Series A stages, with a typical check size ranging from $4M to $36M. The fund is known for supporting companies that contribute to sustainability and technological advancements. By identifying and nurturing trailblazing companies, Humboldt Fund helps bring emerging biotech enterprises to global markets, positioning itself as a key player in the future of biotechnological innovation.